US Subpoena For Sun Amid Pricing Heat
This article was originally published in PharmAsia News
Executive Summary
US lawmakers continue to scrutinize drug firms amid ongoing concerns over price-related issues and their impact on healthcare costs. The US Justice Department’s antitrust division has now subpoenaed Sun Pharma for information pertaining to generic drugs, pricing and certain company records, though the Indian firm claimed the move would have no immediate impact on its earnings.
You may also be interested in...
What Does 2017 Hold For Pharma?
Few would argue that 2016 threw a number of curveballs into the global arena. With the New Year upon us, Scrip took a deep breath and asked a number of internal and external contributors across the pharma and biotech spectrum for their expectations for 2017.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet